Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI

Phase 4

Conditions: Coronary Heart Disease

Interventions: Drug: Clopidogrel

First Posted Date: 2016-12-30

Last Posted Date: 2016-12-30

Lead Sponsor: Xijing Hospital

Target Recruit Count: 120

Registration Number: NCT03006835

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Phase 4

Completed

Conditions: Ischemic Stroke
Peripheral Artery Disease
Diabetes Mellitus, Type 2

Interventions: Drug: Clopidogrel
Drug: Cilostazol

First Posted Date: 2016-12-06

Last Posted Date: 2020-12-29

Lead Sponsor: University of Ioannina

Target Recruit Count: 826

Registration Number: NCT02983214

Locations: 🇬🇷
Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina, Epirus, Greece

Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study

Not Applicable

Conditions: Ischemic Attack, Transient
Stroke, Acute

Interventions: Drug: Sanchitongshu
Drug: placebo of Sanchitongshu
Drug: Aspirin
Drug: placebo of clopidogrel
Drug: Clopidogrel

First Posted Date: 2016-11-29

Last Posted Date: 2016-11-29

Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 120

Registration Number: NCT02975076

SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study

Phase 4

Conditions: Peripheral Arterial Disease

Interventions: Drug: Sarpogrelate SR 300mg
Drug: Clopidogrel

First Posted Date: 2016-11-09

Last Posted Date: 2017-07-27

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 272

Registration Number: NCT02959606

Locations: 🇰🇷
Seung-Kee Min,, Seoul, Korea, Republic of

Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk

Phase 3

Conditions: Atrial Fibrillation

Interventions: Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2016-11-09

Last Posted Date: 2016-11-09

Lead Sponsor: Chuncheon Sacred Heart Hospital

Target Recruit Count: 1500

Registration Number: NCT02960126

Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease

Conditions: MCA - Middle Cerebral Artery Dissection

First Posted Date: 2016-11-02

Last Posted Date: 2016-11-02

Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Target Recruit Count: 1000

Registration Number: NCT02953405

Locations: 🇰🇷
SNUBH, Seoul, Korea, Republic of

Migraine Prophylaxis With Clopidogrel Trial

Phase 4

Conditions: Migraine

Interventions: Drug: clopidogrel

First Posted Date: 2016-10-19

Last Posted Date: 2021-08-27

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 50

Registration Number: NCT02938182

Locations: 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction

Phase 4

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Ticagrelor
Drug: Clopidogrel

First Posted Date: 2016-10-12

Last Posted Date: 2020-12-23

Lead Sponsor: Medical University of Warsaw

Target Recruit Count: 60

Registration Number: NCT02931045

Locations: 🇳🇱
Laboratory of Experimental Clinical Chemistry, Academic Medical Centre of the University of Amsterdam, Amsterdam, Netherlands
🇵🇱
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland